Navigation Links
Albemarle(R) Announces Custom Manufacturing Alliance with PharmaCore(R)
Date:2/15/2010

BATON ROUGE, La., Feb. 15 /PRNewswire-FirstCall/ -- Albemarle Corporation (NYSE: ALB), a leading global provider of custom manufacturing services, announced today it will partner with PharmaCore to provide manufacturing capabilities for customers with projects that require high volume capacity.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050801/ALBEMARLELOGO )

This alliance allows a seamless technology transfer from PharmaCore to Albemarle, offering PharmaCore customers long term, higher volume capacity for their pharmaceutical projects.  Albemarle's custom manufacturing capabilities include a network of manufacturing assets in South Haven, Mich., Tyrone, Pa. and Orangeburg, S.C., providing Active Pharmaceutical Ingredients (APIs) and advanced pharmaceutical intermediate production in a broad range of scale and chemistries.  

"We are happy that PharmaCore chose Albemarle's custom manufacturing business unit, Fine Chemistry Services (FCS), to expand their expertise as a custom synthesis provider for their customers," said Steve LeVan, Albemarle's vice president of FCS.  "I am confident that PharmaCore's valued customers will benefit from our premier service and production capabilities and look forward to partnering with each of them to bring their products to market quickly and effectively."

"Our customers already benefit from PharmaCore's med-chem services through current Good Manufacturing Practices (cGMP) pilot plant capabilities.  This new partnership with Albemarle will complete the process," said Brian Swierenga, PharmaCore's vice president of GMP operations.  "We have formed long business relationships with many of our customers, synthesizing first batches for toxicology continuing through lab process development and ultimately providing cGMP material for clinical trials.  This new Albemarle partnership offers an opportunity to transfer that learned technology to full-scale manufacturing."

Albemarle's FCS division is a leading provider of products, custom manufacturing and process scale-up services to a wide variety of industries including pharmaceuticals, crop protection and other specialty markets. The FCS division boasts rapid response time and flexible manufacturing, including two cGMP plants in the United States and several custom manufacturing plants in the United States and Europe.

About Albemarle

Albemarle Corporation, headquartered in Baton Rouge, Louisiana, is a leading global developer, manufacturer, and marketer of highly-engineered specialty chemicals for consumer electronics, petroleum refining, utilities, packaging, construction, automotive/transportation, pharmaceuticals, crop protection, food-safety and custom chemistry services.  The Company is committed to global sustainability and is advancing its eco-practices and solutions in its three business segments, Polymer Solutions, Catalysts, and Fine Chemicals. Albemarle employs over 4,100 people and serves customers in approximately 100 countries.  To learn more, visit www.albemarle.com.

About PharmaCore

PharmaCore®, Inc., headquartered in High Point, N.C., is an industry leader in custom organic synthesis, using diverse chemistries to produce pharmaceutical intermediates and API's.  The company's business offerings consist of a variety of chemistry outsourcing functions, including: medicinal chemistry services; chemical process and development; cGMP scale-up; and cGMP analytical services.  PharmaCore has served customers globally since 2000.  Additional information is available at www.pharmacore.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding Albemarle Corporation's business that are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company's Annual Report on Form 10-K.

SOURCE Albemarle Corporation

RELATED LINKS
http://www.albemarle.com

'/>"/>

SOURCE Albemarle Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 2017 ITL Limited, ( ASX: ITD ... erfreut, für das zum 31. Dezember 2016 endende ... Ergebnisse vorlegen zu können. Eine vollständige Präsentation „Ergebnisse ... finden Sie hier . Glanzpunkte ... (Dez. 2015: 1,04 Millionen USD; +104 %) Gewinn ...
(Date:2/24/2017)... 23, 2017 Non-alcoholic steatohepataitis (NASH) ... various drugs being developed for the treatment ... drugs that are in various phases of ... focuses on novel pharmacologic drugs & regenerative ... therapies, recombinant proteins and RNA-based therapeutics, but ...
(Date:2/24/2017)... Research and Markets has announced the addition ... 2016" report to their offering. ... The latest research Urinary Incontinence Drugs Price ... in the global Urinary Incontinence market. The research answers the ... drugs marketed for Urinary Incontinence and their clinical attributes? How are ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... Healthcare Associates of McKinney announced today ... building at 8080 State Highway 121, Suite 210, McKinney, Texas 75070. It is ... 121. , As the practice has grown, the need for more space has been ...
(Date:2/24/2017)... ... February 24, 2017 , ... The California State ... convening academic faculty engaged in or interested in palliative care education and research. The ... be held in North County San Diego on Sept. 28 and 29, 2017, on ...
(Date:2/24/2017)... ... February 24, 2017 , ... Indiana Fiber Network (IFN) ... company later this year. Dyer started as the Chairman of the Management Committee ... establishment of the corporation including the recruitment of investor/owners and development of the business ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... Senior International Elite division on February 12th. Ms. Esparza qualified into this ... elite qualifier competition held in Las Vegas, Nevada. Frida is one of approximately ...
(Date:2/23/2017)... MA (PRWEB) , ... February 23, 2017 , ... ... and Department of Justice jointly issued a letter to withdraw previous ... accordance with their gender identity. The guidance issued in May 2016 by the ...
Breaking Medicine News(10 mins):